First-line therapy for metastatic hormone-sensitive prostate cancer

被引：0
|
作者：
Rexer, Heidrun [1 ,4 ]
Feyerabend, Susan [2 ]
Graefen, Markus [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Studienpraxis Urol, Urologie, Nurtingen, Germany
[3] Organgruppe Prostatakazinom, Arbeitsgemeinschaft Urol Onkologie Deutsch Krebsge, Berlin, Germany
[4] Seestr 11, D-17252 Schwarz, Germany
来源：
AKTUELLE UROLOGIE | 2023年 / 54卷 / 03期
关键词：
D O I：
10.1055/a-2018-9585
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：186 / 188
页数：2
相关论文
共 50 条
  • [31] Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer
    Borque-Fernando, A.
    Perez-Fentes, D. A.
    Rodrigo-Aliaga, M.
    Puente-Vazquez, J.
    Gomez-Iturriaga, A.
    Unda, M.
    Calleja-Hernandez, M. A.
    Cozar-Olmo, J. M.
    alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (10): : 703 - 717
  • [32] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [33] Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer
    Mike Wenzel
    Benedikt Hoeh
    Clara Humke
    Cristina Cano Garcia
    Carolin Siech
    Thomas Steuber
    Markus Graefen
    Miriam Traumann
    Luis Kluth
    Felix K. H. Chun
    Philipp Mandel
    World Journal of Urology, 43 (1)
  • [34] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
  • [35] Comparison of chemotherapy with chemohormonal therapy as first-line therapy-for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study
    Sledge, GW
    Hu, P
    Falkson, G
    Tormey, D
    Abeloff, M
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 262 - 266
  • [36] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
    Junker, Annette
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
  • [37] Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy
    Ye, Shi-jie
    Huang, Rui-da
    Fei, Xin
    Tao, Zhu-lei
    Liu, Wei-hua
    Ma, Qi
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1188) : 703 - 708
  • [38] Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
    Francini, Edoardo
    Yip, Steven
    Ahmed, Shubidito
    Li, Haocheng
    Ardolino, Luke
    Evan, Carolyn P.
    Kaymakcalan, Marina
    Shaw, Grace K.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Alimohamed, Nimira S.
    Joshua, Anthony M.
    Heng, Daniel Y. C.
    Sweeney, Christopher J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 130 - 134
  • [39] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
  • [40] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Arnold Lee
    Targeted Oncology, 2023, 18 : 793 - 800
12345